AKESO(HK:09926) Jin Rong Jie·2025-12-12 06:53Group 1 - The Hong Kong Stock Connect innovative drug sector is experiencing a rebound, with the high-volatility Hong Kong Stock Connect innovative drug ETF (520880) rising over 1% after a four-day decline, indicating a potential end to this downward trend [1] - This week, the ETF has seen a significant inflow of "bottom-fishing" funds, with a cumulative net subscription amount exceeding 130 million yuan [1] - Leading stocks in the sector include Kangfang Biotech, which surged over 6.8%, and other notable gainers such as Innovent Biologics and BeiGene [3] Group 2 - Kangfang Biotech's PD-1/CTLA-4 dual-specific antibody, Kadcyla, has received FDA approval to conduct a Phase III clinical trial for treating HER2-negative, unresectable, or metastatic gastric or gastroesophageal junction adenocarcinoma [3] - According to Ping An Securities, the rise of innovative drugs is sustainable from three perspectives: business development, commercialization, and policy [3] - The report suggests focusing on companies with rich pipelines, those with high potential single products, and firms leading in advanced technology platforms [3] Group 3 - The Hong Kong innovative drug sector has been in a correction phase since early September, with nearly three months of adjustment, enhancing the cost-effectiveness of investments [3] - The Hong Kong Stock Connect innovative drug ETF (520880) is the largest in its category, with a scale of 2.142 billion yuan and an average daily trading volume of 458 million yuan since its inception [4] - The index tracked by the ETF has a significant concentration of leading stocks, with the top ten holdings accounting for over 72% of the total weight, indicating strong leadership in the innovative drug sector [4]